<http://purl.obolibrary.org/obo/CHEBI_50906>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "chemical role" .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://geneontology.org/lego/evidence>
          <http://model.geneontology.org/0.3115745036483929> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5637812" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-09-18" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://model.geneontology.org/1142944135> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://model.geneontology.org/1142944136>
] .

<http://model.geneontology.org/1142944133>
        a       <http://www.w3.org/2002/07/owl#NamedIndividual> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "Ligand-responsive EGFR cancer variants harbor mutations in the kinase domain or point mutations in the extracellular domain. These altered EGFR proteins are able to signal in the absence of ligands, but their ligand binding ability is preserved and downstream signaling is potentiated when ligand is available (Greulich et al. 2005, Lee et al. 2006)." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Signaling by Ligand-Responsive EGFR Variants in Cancer" ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5637812" , "Reviewed: Savas, S, 2011-11-15" , "Edited: Matthews, L, 2011-11-07" , "Reviewed: Greulich, H, 2011-11-15" , "Edited: Wu, G, 2011-11-07" , "Edited: Gillespie, ME, 2011-11-07" , "Edited: Haw, R, 2011-11-07" , "Edited: D'Eustachio, P, 2011-11-07" , "Authored: Orlic-Milacic, M, 2011-11-04" , "Edited: Jassal, B, 2011-11-07" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-09-18" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/BFO_0000051>
        a       <http://www.w3.org/2002/07/owl#ObjectProperty> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "has part" .

<http://purl.obolibrary.org/obo/RO_0002327>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "enables" .

<http://purl.org/pav/providedBy>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/CHEBI_36080>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "chebi protein" .

<http://purl.obolibrary.org/obo/RO_0002406>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly activates (process to process)" .

<http://purl.obolibrary.org/obo/BFO_0000002>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Continuant" .

<http://purl.obolibrary.org/obo/GO_0008150>
        a       <http://www.w3.org/2002/07/owl#Class> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Biological Process" .

<http://purl.obolibrary.org/obo/RO_0002334>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "regulated by" .

<http://purl.obolibrary.org/obo/BFO_0000015>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Process" .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://geneontology.org/lego/evidence>
          <http://model.geneontology.org/0.2901405025322418> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5637812" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-09-18" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000050> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://model.geneontology.org/1142944135> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://model.geneontology.org/1142943460>
] .

<http://model.geneontology.org/1142943460>
        a       <http://purl.obolibrary.org/obo/GO_0008150> , <http://www.w3.org/2002/07/owl#NamedIndividual> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "The pathway \"Signaling by EGFR in Cancer\" shows signaling by constitutively active EGFR cancer variants in the context of \"Signaling by EGFR\", allowing users to compare cancer events with the wild-type EGFR events. Red lines emphasize cancer related events and physical entities, while wild-type entities and events are shaded. Please refer to \"Signaling by Ligand-Responsive EGFR Variants in Cancer\", \"Signaling by EGFRvIII in Cancer\" and \"Signaling by Overexpressed Wild-Type EGFR in Cancer\" for detailed pathway summations." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Signaling by EGFR in Cancer" ;
        <http://purl.obolibrary.org/obo/BFO_0000051>
                <http://model.geneontology.org/1142944133> , <http://model.geneontology.org/1142944135> , <http://model.geneontology.org/1142944137> ;
        <http://purl.org/dc/elements/1.1/contributor>
                "Reviewed: Greulich, H, 2011-11-15" , "Edited: D'Eustachio, P, 2011-11-07" , "https://reactome.org/content/detail/R-HSA-5637812" , "Edited: Haw, R, 2011-11-07" , "Edited: Matthews, L, 2011-11-07" , "Reviewed: Savas, S, 2011-11-15" , "Edited: Jassal, B, 2011-11-07" , "Edited: Gillespie, ME, 2011-11-07" , "Authored: Orlic-Milacic, M, 2011-11-04" , "Edited: Wu, G, 2011-11-07" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-09-18" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/RO_0002234>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "has output" .

<http://purl.obolibrary.org/obo/RO_0002413>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly provides input for (process to process)" .

<http://purl.obolibrary.org/obo/CHEBI_24431>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "chemical entity" .

<http://purl.obolibrary.org/obo/BFO_0000050>
        a       <http://www.w3.org/2002/07/owl#ObjectProperty> ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "part of" .

<http://purl.obolibrary.org/obo/GO_0032991>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "protein-containing complex" .

<http://purl.org/dc/elements/1.1/source>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://model.geneontology.org/1142944137>
        a       <http://www.w3.org/2002/07/owl#NamedIndividual> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "Signaling by EGFR is frequently activated in cancer through genomic amplification of the EGFR locus, resulting in over-expression of the wild-type protein (Wong et al. 1987)." ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Signaling by Overexpressed Wild-Type EGFR in Cancer" ;
        <http://purl.org/dc/elements/1.1/contributor>
                "Reviewed: Savas, S, 2011-11-15" , "Reviewed: Greulich, H, 2011-11-15" , "Edited: Gillespie, ME, 2011-11-07" , "Edited: Haw, R, 2011-11-07" , "Edited: Jassal, B, 2011-11-07" , "Edited: Wu, G, 2011-11-07" , "Edited: Matthews, L, 2011-11-07" , "https://reactome.org/content/detail/R-HSA-5637812" , "Edited: D'Eustachio, P, 2011-11-07" , "Authored: Orlic-Milacic, M, 2011-11-04" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-09-18" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/RO_0002333>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "enabled by" .

<http://model.geneontology.org/0.3115745036483929>
        a       <http://www.w3.org/2002/07/owl#NamedIndividual> , <http://purl.obolibrary.org/obo/ECO_0000313> ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5637812" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-09-18" ;
        <http://purl.org/dc/elements/1.1/source>
                "PMID:11087732" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/RO_0002305>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "causally upstream of with a negative effect" .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5637812" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-09-18" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://model.geneontology.org/1142943460> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://model.geneontology.org/1142944137>
] .

<http://purl.obolibrary.org/obo/RO_0002233>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "has input" .

<http://model.geneontology.org/1142944136>
        a       <http://www.w3.org/2002/07/owl#NamedIndividual> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "In glioblastoma, the most prevalent EGFR mutation, present in ~25% of tumors, is the deletion of the ligand binding domain of EGFR, accompanied with amplification of the mutated allele, which results in over-expression of the mutant protein known as EGFRvIII. EGFRvIII mutant is not able to bind a ligand, but dimerizes and autophosphorylates spontaneously and is therefore constitutively active (Fernandes et al. 2001). Point mutations in the extracellular domain of EGFR are also frequently found in glioblastoma, but ligand binding ability and responsiveness are preserved (Lee et al. 2006). <br>Similar to EGFR kinase domain mutants, EGFRvIII mutant needs to maintain association with the chaperone heat shock protein 90 (HSP90) for proper functioning (Shimamura et al. 2005, Lavictoire et al. 2003). CDC37 is a co-chaperone of HSP90 that acts as a scaffold and regulator of interaction between HSP90 and its protein kinase clients. CDC37 is frequently over-expressed in cancers involving mutant kinases and acts as an oncogene (Roe et al. 2004, reviewed by Gray Jr. et al. 2008). <br>Expression of EGFRvIII mutant results in aberrant activation of downstream signaling cascades, namely RAS/RAF/MAP kinase signaling and PI3K/AKT signaling, and possibly signaling by PLCG1, which leads to increased cell proliferation and survival, providing selective advantage to cancer cells that harbor EGFRvIII (Huang et al. 2007). <br> EGFRvIII mutant does not autophosorylate on the tyrosine residue Y1045, a docking site for CBL, and is therefore unable to recruit CBL ubiquitin ligase, which enables it to escape degradation (Han et al. 2006)" ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Constitutive Signaling by EGFRvIII" ;
        <http://purl.org/dc/elements/1.1/contributor>
                "Edited: Wu, G, 2011-11-07" , "Reviewed: Savas, S, 2011-11-15" , "https://reactome.org/content/detail/R-HSA-5637812" , "Edited: D'Eustachio, P, 2011-11-07" , "Edited: Gillespie, ME, 2011-11-07" , "Authored: Orlic-Milacic, M, 2011-11-04" , "Edited: Haw, R, 2011-11-07" , "Reviewed: Greulich, H, 2011-11-15" , "Edited: Jassal, B, 2011-11-07" , "Edited: Matthews, L, 2011-11-07" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-09-18" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/RO_0002304>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "causally upstream of with a positive effect" .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5637812" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-09-18" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://model.geneontology.org/1142943460> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://model.geneontology.org/1142944135>
] .

<http://purl.obolibrary.org/obo/RO_0002411>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "causally upstream of" .

<http://purl.obolibrary.org/obo/GO_0005575>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Cellular Component" .

<http://geneontology.org/lego/evidence>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/RO_0002629>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly positively regulates" .

<http://purl.org/dc/elements/1.1/date>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://geneontology.org/lego/modelstate>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/CHEBI_33695>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "chebi gene" .

<http://purl.obolibrary.org/obo/RO_0001025>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "located in" .

<http://purl.obolibrary.org/obo/ECO_0000313>
        a       <http://www.w3.org/2002/07/owl#Class> .

<http://purl.obolibrary.org/obo/GO_0003674>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Molecular Function" .

<http://model.geneontology.org/1142944135>
        a       <http://www.w3.org/2002/07/owl#NamedIndividual> , <http://purl.obolibrary.org/obo/GO_0008150> ;
        <http://www.w3.org/2000/01/rdf-schema#comment>
                "EGFRvIII (EGFR V30_R297delinsG) is the most prevalent EGFR variant in glioblastoma, but it is also found in other cancer types. In-frame deletion of the ligand binding domain in EGFRvIII is frequently accompanied with genomic amplification, resulting in over-expression of EGFRvIII. EGFRvIII dimerizes and autophosphorylates spontaneously and is therefore constitutively active (Fernandes et al. 2001)" ;
        <http://www.w3.org/2000/01/rdf-schema#label>
                "Signaling by EGFRvIII in Cancer" ;
        <http://purl.obolibrary.org/obo/BFO_0000050>
                <http://model.geneontology.org/1142943460> ;
        <http://purl.obolibrary.org/obo/BFO_0000051>
                <http://model.geneontology.org/1142944136> ;
        <http://purl.org/dc/elements/1.1/contributor>
                "Authored: Orlic-Milacic, M, 2011-11-04" , "Reviewed: Greulich, H, 2011-11-15" , "Reviewed: Savas, S, 2011-11-15" , "Edited: Gillespie, ME, 2011-11-07" , "Edited: Haw, R, 2011-11-07" , "Edited: Jassal, B, 2011-11-07" , "Edited: D'Eustachio, P, 2011-11-07" , "Edited: Wu, G, 2011-11-07" , "Edited: Matthews, L, 2011-11-07" , "https://reactome.org/content/detail/R-HSA-5637812" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-09-18" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://model.geneontology.org/0.2901405025322418>
        a       <http://www.w3.org/2002/07/owl#NamedIndividual> , <http://purl.obolibrary.org/obo/ECO_0000313> ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5637812" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-09-18" ;
        <http://purl.org/dc/elements/1.1/source>
                "PMID:11087732" ;
        <http://purl.org/pav/providedBy>
                "https://reactome.org" .

<http://purl.obolibrary.org/obo/RO_0002429>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "involved in positive regulation_of" .

<http://purl.obolibrary.org/obo/RO_0000087>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "has role" .

[ a       <http://www.w3.org/2002/07/owl#Axiom> ;
  <http://purl.org/dc/elements/1.1/contributor>
          "https://reactome.org/content/detail/R-HSA-5637812" ;
  <http://purl.org/dc/elements/1.1/date>
          "2018-09-18" ;
  <http://purl.org/pav/providedBy>
          "https://reactome.org" ;
  <http://www.w3.org/2002/07/owl#annotatedProperty>
          <http://purl.obolibrary.org/obo/BFO_0000051> ;
  <http://www.w3.org/2002/07/owl#annotatedSource>
          <http://model.geneontology.org/1142943460> ;
  <http://www.w3.org/2002/07/owl#annotatedTarget>
          <http://model.geneontology.org/1142944133>
] .

<http://purl.obolibrary.org/obo/RO_0002024>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly positively regulated by" .

<http://purl.obolibrary.org/obo/BFO_0000066>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "occurs in" .

<http://purl.obolibrary.org/obo/RO_0002630>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly negatively regulates" .

<http://purl.org/dc/elements/1.1/contributor>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/RO_0002408>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly inhibits (process to process)" .

<http://model.geneontology.org/-1522733719>
        a       <http://www.w3.org/2002/07/owl#Ontology> ;
        <http://geneontology.org/lego/modelstate>
                "development" ;
        <http://purl.org/dc/elements/1.1/contributor>
                "https://reactome.org/content/detail/R-HSA-5637812" ;
        <http://purl.org/dc/elements/1.1/date>
                "2018-09-18" ;
        <http://purl.org/dc/elements/1.1/title>
                "Reactome:unexpanded:Signaling by EGFRvIII in Cancer" .

<http://purl.obolibrary.org/obo/RO_0002430>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "involved in negative regulation_of" .

<http://purl.org/dc/elements/1.1/title>
        a       <http://www.w3.org/2002/07/owl#AnnotationProperty> .

<http://purl.obolibrary.org/obo/RO_0002428>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "involved in regulation of" .

<http://purl.obolibrary.org/obo/RO_0002023>
        <http://www.w3.org/2000/01/rdf-schema#label>
                "directly negatively regulated by" .
